source
- Eli Lilly to acquire Ajax Therapeutics for up to $2.3 billion to develop improved JAK inhibitorEli Lilly announced Monday it will purchase Ajax Therapeutics, a biotech based in New York and Cambridge, Massachusetts, in a deal valued at up to $2.3 billion. The transaction includes cash up fr…
- Eli Lilly to pay up to $2.3B for Ajax's JAK inhibitor in cancer dealEli Lilly announced a new agreement with Ajax Therapeutics to acquire rights to a JAK inhibitor called Kyle LaHucik for cancer treatment. The transaction could be worth up to $2.3 billion, reflect…